Accendra Health Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q4 2025 revenue was nearly $2.8 billion, reflecting a year-over-year increase of over 3%. Full-year revenue also grew slightly compared to 2024.

Adjusted EBITDA: Q4 adjusted EBITDA was $90 million, down from $102.5 million in Q4 2024. Full-year adjusted EBITDA was $375 million, showing slight growth from the previous year.

Cash Flow: Operating cash flow for Q4 was $68 million, with the continuing operations generating $135 million. Free cash flow for Q4 was $18 million and $98 million for the full year.

Debt: Net debt decreased to $1.8 billion, down $315 million from Q3 2025, aided by $342 million from the divestiture of the Products & Healthcare Services business.

2Strategic Updates and Business Highlights

Market Position: Accendra Health serves approximately 300 million Americans, focusing on home-based care for chronic conditions. The company has strong brand recognition through its Byram and Apria brands.

Technology Investments: The company is leveraging technology to enhance customer experience and operational efficiency, including the upcoming launch of the MyApria app.

Divestiture Completion: The sale of the former Products & Healthcare Services business was completed on December 31, 2025, allowing Accendra to focus on core operations and improve margins.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected annual revenue between $2.55 billion and $2.65 billion, impacted by the loss of a large commercial payer, which will account for a $300 million revenue reduction.

Adjusted EBITDA Guidance: Projected between $335 million and $355 million for 2026, with anticipated cost reductions and volume growth partially mitigating the impact of the commercial payer loss.

Free Cash Flow: Expected to be at least $100 million in 2026, with a focus on debt reduction and capital structure optimization.

4Bad News, Challenges, or Points of Concern

Contract Loss Impact: The loss of a significant commercial payer is expected to reduce revenue by approximately $300 million in 2026, with a significant impact on Q1 and ongoing throughout the year.

Inflationary Pressures: Increased costs due to inflation and rising product prices are affecting margins, although management views this as an opportunity to improve pricing strategies.

Collection Rates: A weaker collection rate in 2025 compared to 2024 has been noted, which is expected to improve in 2026 as technology investments yield results.

5Notable Q&A Insights

Investment Focus: Management emphasized that while debt reduction is the priority for 2026, there will be targeted investments in technology to enhance customer experience and operational efficiency.

Revenue Recapture: The company is working to fill the revenue gap from the lost payer through new agreements, including a preferred provider agreement with Optum, although it is acknowledged that full replacement of lost revenue may not be achievable.

Cost Management: Management is actively identifying cost reduction opportunities, particularly related to stranded costs from the divestiture, which will no longer be separately reported post-2025. Overall, Accendra Health is positioned for growth in a challenging environment, with a focus on leveraging technology and optimizing its capital structure while navigating significant revenue headwinds from lost contracts.